» Articles » PMID: 12414516

Differentiation Between High- and Low-grade Astrocytoma Using a Human Recombinant Antibody to the Extra Domain-B of Fibronectin

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2002 Nov 5
PMID 12414516
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Different fibronectin (FN) isoforms are generated by the alternative splicing of the primary FN transcript. We previously demonstrated that the isoform containing the extra domain B sequence of fibronectin (B-FN), a complete type-III-homology repeat, is a marker of angiogenesis that accumulates around neovasculature only during angiogenic processes. We produced a single-chain human recombinant antibody (scFv), L19, which reacts specifically with B-FN and selectively targets tumor vasculature in vivo. We used this scFv and an antibody against a pan-endothelial marker (Factor VIII) in a double-staining procedure on specimens of low- and high-grade astrocytomas to determine the percentage of B-FN-positive vessels, (denominating the resulting value angiogenic index [AI]). Compared to vascular density and proliferative activity (evaluated using antibodies to Factor VIII and Ki67, respectively), AI correlated better with tumor grade (1.6 +/- 2.6% and 92.0 +/- 8.7% of B-FN-positive vessels in low- and high-grade astrocytomas, respectively) and was a more precise diagnostic tool than either of the two conventional methods. In fact, discriminating analysis using these three parameters showed that only AI accurately classified 100% of the cases studied, compared to 64% and 89% correctly diagnosed by vascular density and of proliferating cells, respectively.

Citing Articles

The impact of inflammation and acute phase activation in cancer cachexia.

Robinson T, Hamidi T, Counts B, Guttridge D, Ostrowski M, Zimmers T Front Immunol. 2023; 14:1207746.

PMID: 38022578 PMC: 10644737. DOI: 10.3389/fimmu.2023.1207746.


Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.

Zhang Z, Liu C, Wang M, Sun R, Yang Z, Hua Z J Immunother Cancer. 2023; 11(8).

PMID: 37586774 PMC: 10432677. DOI: 10.1136/jitc-2023-007199.


Nucleic acid drug vectors for diagnosis and treatment of brain diseases.

Lu Z, Shen J, Yang J, Wang J, Zhao R, Zhang T Signal Transduct Target Ther. 2023; 8(1):39.

PMID: 36650130 PMC: 9844208. DOI: 10.1038/s41392-022-01298-z.


CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B.

Zhang Z, Liu C, Yang Z, Yin H Cells. 2022; 11(18).

PMID: 36139437 PMC: 9496916. DOI: 10.3390/cells11182863.


Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.

Hooper A, Marquette K, Chang C, Golas J, Jain S, Lam M Mol Cancer Ther. 2022; 21(9):1462-1472.

PMID: 35793468 PMC: 9446899. DOI: 10.1158/1535-7163.MCT-22-0099.


References
1.
Nilsson F, Kosmehl H, Zardi L, Neri D . Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001; 61(2):711-6. View

2.
Carnemolla B, Leprini A, Allemanni G, Saginati M, Zardi L . The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem. 1992; 267(34):24689-92. View

3.
Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A . Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer. 2001; 94(4):579-85. DOI: 10.1002/ijc.1505. View

4.
Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A . Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. 2002; 99(5):1659-65. DOI: 10.1182/blood.v99.5.1659. View

5.
Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L . Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol. 2002; 20(3):264-9. DOI: 10.1038/nbt0302-264. View